Asia Business News
Biota Holdings Limited (ASX:BTA) Quarterly Royalties from Relenza
Thursday July 24, 10:30 AM
Melbourne, Australia, July 24, 2008 - (ABN Newswire) - Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (LON:GSK)(PINK:GLAXF) that indicative royalties from Relenza were $0.4m during the three months ended 30 June 2008, on sales of $6.2m.
Indicative royalties and sales advised by GSK, by quarter is summarised below:
----------------------------------------------------
Q1 Q2 Q3 Q4 Total
----------------------------------------------------
Indicative royalties $m 4.5 12.0 4.4 0.4 21.3
Indicative sales $m 63.9 171.4 62.5 6.2 304.4
----------------------------------------------------
Biota will report full year royalties from Relenza of $20.5m, reconciled as follows:
----------------------------------------------------
$m
----------------------------------------------------
Indicative royalties per above 21.3
Adjustment in respect of an
overpayment by GSK in 2007 (0.2)
Adjustment by GSK on payment, due to
a difference between actual
royalties and indicative royalties
previously advised (0.6)
----------------------------------------------------
Actual royalties reported 20.5
----------------------------------------------------
Biota CEO, Peter Cook said "Whilst the royalty is low, it reflects the off season in the Northern hemisphere. Biota and GSK recently concluded their litigation and we look forward to the normalisation of our relationship and developing the Relenza franchise."Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to MedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals. Inverness Medical markets Biota's co-developed OIA FLU influenza diagnostics.
Relenza(TM) is a registered trademark of the GlaxoSmithKline group of companies.
BioStar(R) OIA(R) FLU and BioStar(R) OIA(R) FLU A/B are registered trademarks of Inverness Medical.
About BIOTA HOLDINGS LIMITED:
Biota is Australia's leading anti-infective drug development company, based in Melbourne.
Biota's initial success was the discovery of zanamivir, the first-in-class neuraminidase inhibitor for the treatment and prevention of influenza. Zanamivir is licensed to GlaxoSmithKline and marketed as Relenza(tm). Relenza is used to treat seasonal influenza and is currently being stockpiled by various governments for defence against possible pandemic outbreaks of avian (bird) influenza.
Contact:
Investor / Analyst Enquiries Peter Cook Biota Holdings Limited T: +61 3 9915 3720 Damian Lismore T: +61 3 9915 3721 Media Enquiries Tim Duncan or Nerida Mossop Hinton & Associates T: +61 3 9600 1979 M:+61 437 361 433
Source:
BIOTA HOLDINGS LIMITED
Copyright (C) 2008 ABN Newswire. All rights reserved.
Next Article: IBA Health Group Limited's (ASX:IBA) iSOFT Wins Regional Health Project In Mexico
Previous article: Abu Dhabi Ship Building (ABD:ADSB) to Build 12 New Patrol Boats for UAE Coast Guard
Top Headlines
NZX move may provide opportunities for small companies
Monday September 22, 08:31 PM - NZPA
NZX Ltd is exploring ways of working with a competitor to the London Stock Exchange that might suit small companies. .. Read More
Short selling unlikely to be regulated in NZ
Monday September 22, 07:26 PM - NZPA
New Zealand will not be joining Australia in regulating the short selling of shares because the behaviour that triggered the .. Read More
NZ sharemarket leaps after US financial bailout
Monday September 22, 06:56 PM - NZPA
When the US sharemarket leaps the New Zealand sharemarket leaps too and that is how it was today. .. Read More
Calculators
Copyright © 2008 Yahoo! All rights reserved.
Yahoo!Xtra: A Yahoo!7/Telecom New Zealand Company.